Begin main content

Midostaurin (TBD) for Acute Myeloid Leukemia – Details

Project Number pCODR 10108
Brand Name Brand Name TBD
Generic Name Midostaurin
Tumour Type Leukemia
Indication Acute Myeloid Leukemia
Funding Request For the treatment of newly diagnosed acute myeloid leukemia (AML) patients who are FLT3 mutation-positive.
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Novartis Pharmaceuticals Canada Inc.
Submitter Novartis Pharmaceuticals Canada Inc.
Submission Date (Target Date) June 12, 2017
Submission Type New Drug
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ June 26, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.